On Saturday, Zydus Lifesciences said that the US health agency has given the company permission to distribute Silodosin capsules in the US for the treatment of benign prostatic hyperplasia.
The US Food and Drug Administration (USFDA) has also given the business final approval to market Pregabalin capsules in various strengths, according to a statement from the Ahmedabad-based pharmaceutical company. The indication for silodosin capsules, commonly known as benign prostate enlargement, is to treat the signs and symptoms of an enlarged prostate gland (benign prostatic hyperplasia or BPH).
Pregabalin capsules are recommended for treating shingles (herpes zoster) infection and discomfort brought on by diabetes-related nerve damage. Additionally, it is used to treat fibromyalgia pain and the nerve pain brought on by spinal cord injuries.
According to IQVIA data, the US market saw yearly sales of $14 million for Silodosin capsules and $242 million for Pregabalin capsules, respectively.
